Viridian Therapeutics Q1 net loss $68.2M; VRDN-001 chronic TED data expected June/July 2023

Viridian Therapeutics, Inc.\DE

2023-Q1 EPS reported -$1.61 revenue$98,000

Net loss of $68.2M for Q1 2023 vs. $25.7M in Q1 2022; R&D expenses $50.7M including $15M upfront to Enable Injections.
Cash and short-term investments $373.9M at March 31, 2023, down from $424.6M at Dec 31, 2022; expected to fund into H2 2025.
Topline data from VRDN-001 proof-of-concept study in chronic TED expected June/July 2023; THRIVE-2 Phase 3 initiation planned mid-2023.
Lead subcutaneous (SC) program selection expected year-end 2023; IND for VRDN-003 to be filed Q2 2023.
Appointed Tony Casciano as CCO, Thomas Ciulla as CDO, and other senior executives during Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viridian Therapeutics, Inc.\DE reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the first quarter ended March 31, 2023.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-139409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.